Clinical trials
Breast Cancer (Triple Negative Breast Cancer (TNBC)) clinical trials
Below are recruiting breast cancer (triple negative breast cancer (tnbc)) clinical trials, each written for real people, not researchers. We’re tracking 254 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06547840RecruitingPhase 1
Study of MOv18 IgE for ovarian, endometrial, and breast cancers with a specific marker
This trial tests a new antibody treatment called MOv18 IgE for patients with advanced ovarian, endometrial, or triple-negative breast cancers that have a protein called folate receptor alpha (FRα) on their tumor cells. The goal is to see if the treatment is safe and effective.
BristolAges 18 years+ - NCT06568692RecruitingPhase 2
Study of PCS6422 with capecitabine for advanced breast cancer
This trial tests a new drug combination (PCS6422 plus capecitabine) for people with advanced or metastatic breast cancer that has not responded to other treatments. The goal is to see if adding PCS6422 can make the chemotherapy work better.
Tucson, ArizonaAges 18 years+ - NCT06577987RecruitingPhase 1
Study of CID-078 for advanced solid tumors
This trial tests an experimental drug called CID-078 for people with advanced solid tumors that have stopped responding to other treatments. It aims to find the right dose and see if the drug can shrink tumors.
Sarasota, FloridaAges 12 years+ - NCT06582615Recruiting
MIND diet for better brain health during breast cancer treatment
This study tests whether a special diet (called the MIND diet) can help with thinking and memory in women being treated for triple negative breast cancer. Participants will receive nutrition coaching and support to see if it improves brain function.
New Haven, ConnecticutAges 40–65 - NCT06586047RecruitingEarly Phase 1
PSMA PET scan for triple-negative breast cancer
This trial uses a special PET scan to see if PSMA, a protein on some cancer cells, can help detect triple-negative breast cancer that has spread to other parts of the body.
Iowa City, IowaAges 18–90 - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT06606730RecruitingPhase 3
Personalized pembrolizumab after strong chemo response for early triple-negative breast cancer
This trial is for people with early triple-negative breast cancer who had a strong response to chemotherapy combined with pembrolizumab before surgery. It aims to find the best way to continue using pembrolizumab after surgery to reduce the risk of cancer coming back.
BrusselsAges 18 years+ - NCT06627712RecruitingPhase 3
SBRT with immunotherapy and chemo for early-stage triple-negative breast cancer
This trial tests whether combining targeted radiation (SBRT) with immunotherapy (PD-1 inhibitor) and chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer that has not spread far. It aims to find a more effective treatment option.
Sichuan, ChengduAges 18–65 - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06678048RecruitingPhase 2
Arsenous acid for hard-to-treat triple-negative breast cancer
This trial tests a medicine called arsenous acid for people with triple-negative breast cancer that has not responded to at least two prior treatments. If you join, you will get arsenous acid plus one of four chemotherapy drugs to see if the combination can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT06682195RecruitingPhase 2
Chemo plus toripalimab before surgery for TNBC
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
Nanchang, JiangxiAges 18–70 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06692725Recruiting
Lighter chemo with immunotherapy for triple-negative breast cancer
This trial tests whether using less chemotherapy combined with immunotherapy before surgery works well for people with stage II or III triple-negative breast cancer. The goal is to reduce side effects while still being effective.
Beijing, Beijing MunicipalityAges Any age - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06700382Recruiting
Capecitabine for TNBC after incomplete response
This trial looks at different ways to use the chemotherapy drug capecitabine for people with triple-negative breast cancer who still have cancer cells after initial treatment and surgery. It aims to find the best approach to improve outcomes.
Beijing, Beijing MunicipalityAges Any age - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06735131RecruitingPhase 2
Radiation and immunotherapy for advanced triple-negative breast cancer
This study tests a combination of radiation therapy and immunotherapy for people with advanced triple-negative breast cancer who haven't had chemotherapy for their advanced disease. It aims to see if adding radiation to standard chemotherapy can help shrink tumors and improve outcomes.
Guangzhou, GuangdongAges Any age - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+
Hear when a new Breast Cancer (Triple Negative Breast Cancer (TNBC)) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer (triple negative breast cancer (tnbc))?
- Yes. Clin2 currently lists 254 recruiting breast cancer (triple negative breast cancer (tnbc)) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer (triple negative breast cancer (tnbc)) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer (triple negative breast cancer (tnbc)) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.